loading page

COVID-19, cytokine storm and sigma-1 receptors: potential treatments at hand?
  • Lanfranco R. TronconeOrcid
Lanfranco R. Troncone
Orcid
Instituto Butantan
Author Profile

Abstract

Fluvoxamine, a usual SSRI antidepressant, has agonistic activity on Sigma-1 receptors in ER and inhibits IRE1, an important trigger of cytokine production; Sigma-1 receptor is a target of SARS-COV-2 protein Nsp6 and may start the cytokine storm. The available Sigma-1 agonists may represent important alternatives to treat the cytokine storm and save lives.